Shares of GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) rose 1% to touch a day’s high of Rs 2,869 on 25th August, after the firm announced its entry into the oncology segment in India with Jemperli and Zejula therapies for treating gynaecological cancers.

GSK has entered the oncology segment in India with two therapies for gynaecological cancers — Jemperli and Zejula.

Jemperli is the first and only approved PD-1 immunotherapy in India for second-line treatment of mismatch repair-deficient (dMMR) or microsatellite instability-high advanced or recurrent endometrial cancer. It works by blocking the PD-1 pathway. This helps immune cells detect and attack cancer more effectively.

Zejula is the only approved PARP inhibitor in India for first-line monotherapy maintenance in all biomarker types of advanced ovarian cancer. It offers a convenient treatment option.

Alongside these launches, GSK is introducing Phoenix, a patient support programme to help improve access to these therapies. The company said the treatments aim to address a critical unmet need in women’s cancer care in India.

At 3:30 PM, the shares of GSK Pharma ended 0.31% lower at Rs 2,790 on NSE.

Unlock profitable opportunities every day! Unicorn Signals provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Unicorn Signals and start winning now!